196 related articles for article (PubMed ID: 22269613)
1. The cardiovascular effects of peroxisome proliferator-activated receptor agonists.
Friedland SN; Leong A; Filion KB; Genest J; Lega IC; Mottillo S; Poirier P; Reoch J; Eisenberg MJ
Am J Med; 2012 Feb; 125(2):126-33. PubMed ID: 22269613
[TBL] [Abstract][Full Text] [Related]
2. PPAR agonists for the treatment of cardiovascular disease in patients with diabetes.
Wilding JP
Diabetes Obes Metab; 2012 Nov; 14(11):973-82. PubMed ID: 22443197
[TBL] [Abstract][Full Text] [Related]
3. The cardiovascular effects of peroxisome proliferator-activated receptor agonists.
Kolatkar NS
Am J Med; 2013 Mar; 126(3):e11. PubMed ID: 23410570
[No Abstract] [Full Text] [Related]
4. Therapeutic potential of aleglitazar, a new dual PPAR-α/γ agonist: implications for cardiovascular disease in patients with diabetes mellitus.
Cavender MA; Lincoff AM
Am J Cardiovasc Drugs; 2010; 10(4):209-16. PubMed ID: 20653327
[TBL] [Abstract][Full Text] [Related]
5. Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons.
Tenenbaum A; Motro M; Fisman EZ
Cardiovasc Diabetol; 2005 Sep; 4():14. PubMed ID: 16168052
[TBL] [Abstract][Full Text] [Related]
6. Evolution of peroxisome proliferator-activated receptor agonists.
Chang F; Jaber LA; Berlie HD; O'Connell MB
Ann Pharmacother; 2007 Jun; 41(6):973-83. PubMed ID: 17519293
[TBL] [Abstract][Full Text] [Related]
7. Healing the diabetic heart: modulation of cardiometabolic syndrome through peroxisome proliferator activated receptors (PPARs).
Huang TH; Roufogalis BD
Curr Mol Pharmacol; 2012 Jun; 5(2):241-7. PubMed ID: 22122453
[TBL] [Abstract][Full Text] [Related]
8. Examining the safety of PPAR agonists - current trends and future prospects.
Bortolini M; Wright MB; Bopst M; Balas B
Expert Opin Drug Saf; 2013 Jan; 12(1):65-79. PubMed ID: 23134541
[TBL] [Abstract][Full Text] [Related]
9. The reply.
Friedland S; Filion KB; Eisenberg MJ
Am J Med; 2013 Mar; 126(3):e13. PubMed ID: 23410571
[No Abstract] [Full Text] [Related]
10. The role of various peroxisome proliferator-activated receptors and their ligands in clinical practice.
Derosa G; Sahebkar A; Maffioli P
J Cell Physiol; 2018 Jan; 233(1):153-161. PubMed ID: 28098353
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the dual peroxisome proliferator-activated receptor α/γ agonist aleglitazar to reduce cardiovascular events in patients with acute coronary syndrome and type 2 diabetes mellitus: rationale and design of the AleCardio trial.
Lincoff AM; Tardif JC; Neal B; Nicholls SJ; Rydén L; Schwartz GG; Malmberg K; Buse JB; Henry RR; Wedel H; Weichert A; Cannata R; Grobbee DE
Am Heart J; 2013 Sep; 166(3):429-34. PubMed ID: 24016490
[TBL] [Abstract][Full Text] [Related]
12. PPAR agonists and the metabolic syndrome.
Staels B
Therapie; 2007; 62(4):319-26. PubMed ID: 17983557
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular actions of the peroxisome proliferator-activated receptor-alpha (PPARalpha) agonist Wy14,643.
Zahradka P
Cardiovasc Drug Rev; 2007; 25(2):99-122. PubMed ID: 17614934
[TBL] [Abstract][Full Text] [Related]
14. Potential for peroxisome proliferator-activated receptor-gamma agonists in progression: beyond metabolism.
Fogo AB
Curr Opin Nephrol Hypertens; 2008 May; 17(3):282-5. PubMed ID: 18408479
[TBL] [Abstract][Full Text] [Related]
15. Berberine regulates peroxisome proliferator-activated receptors and positive transcription elongation factor b expression in diabetic adipocytes.
Zhou J; Zhou S
Eur J Pharmacol; 2010 Dec; 649(1-3):390-7. PubMed ID: 20868663
[TBL] [Abstract][Full Text] [Related]
16. Peroxisome proliferator-activated receptor agonists and bladder cancer: lessons from animal studies.
Tseng CH; Tseng FH
J Environ Sci Health C Environ Carcinog Ecotoxicol Rev; 2012; 30(4):368-402. PubMed ID: 23167631
[TBL] [Abstract][Full Text] [Related]
17. The controversial effects of thiazolidinediones on cardiovascular morbidity and mortality.
Stafylas PC; Sarafidis PA; Lasaridis AN
Int J Cardiol; 2009 Jan; 131(3):298-304. PubMed ID: 18684530
[TBL] [Abstract][Full Text] [Related]
18. Strategies for the development of new PPAR agonists in diabetes.
Cavender MA; Nicholls SJ; Lincoff AM
Eur J Cardiovasc Prev Rehabil; 2010 May; 17 Suppl 1():S32-7. PubMed ID: 20489419
[TBL] [Abstract][Full Text] [Related]
19. Targeting components of the stress system as potential therapies for the metabolic syndrome: the peroxisome-proliferator-activated receptors.
Yumuk VD
Ann N Y Acad Sci; 2006 Nov; 1083():306-18. PubMed ID: 17148746
[TBL] [Abstract][Full Text] [Related]
20. Update on PPAR agonists: the clinical significance of FIELD and PROACTIVE.
Robinson JG
Curr Atheroscler Rep; 2007 Jan; 9(1):64-71. PubMed ID: 17169249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
